General Information


We are a clinical stage biotechnology company developing AK002, our wholly owned monoclonal antibody, for the treatment of various eosinophil and mast cell related diseases. AK002 demonstrated pharmacodynamic activity in both of our completed Phase 1 trials, and in the single ascending dose Phase 1 trial involving patients with indolent systemic mastocytosis (“ISM”), patients reported improvements in their symptoms. AK002 selectively targets both eosinophils and mast cells, which are types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs.


Employees: 44
Founded: 2012
Contact Information
Address 75 Shoreway Road, Suite A, San Carlos, CA 94070, US
Phone Number (650) 597-5002
Web Address
View Prospectus: Allakos
Financial Information
Market Cap $635.4mil
Revenues $0 mil (last 12 months)
Net Income $-26.98 mil (last 12 months)
IPO Profile
Symbol ALLK
Exchange NASDAQ
Shares (millions): 7.1
Price range $18.00 - $18.00
Est. $ Volume $128.4 mil
Manager / Joint Managers Goldman Sachs/ Jefferies
CO-Managers William Blair
Expected To Trade: 7/19/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change